{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118291 Protocol V02 04Jun2019', 'Page 43 of 88', 'According to ICH E2A, an AE is any untoward medical occurrence in a subject or clinical', 'investigation subject administered a pharmaceutical product and which does not necessarily have', 'a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended', 'sign (including an abnormal laboratory value), symptom, or disease temporally associated with the', 'use of a medicinal (investigational) product, whether or not related to the medicinal', '(investigational) product.', 'Thus any new sign, symptom or disease, or any clinically significant worsening of an existing sign,', 'symptom or disease compared to the condition at the first visit (including disease treated), should', 'be considered as an AE. Lack of efficacy is not considered as an AE.', 'Each new episode of a chronic disease (e.g., hay fever, allergy, etc.) should be reported as', 'a new AE.', 'Notes:', 'Any new sign or symptom reported by the subject that appears after accidental or intentional', 'overdose or misuse should also be reported as an AE.', 'There should be an attempt to report a diagnosis rather than the signs, symptoms or abnormal', 'laboratory values associated with the report of an AE. However, a diagnosis should be reported', \"only if, in the Investigator's judgment, it is relatively certain. Otherwise, symptoms, signs, or\", 'laboratory values should be used to describe the AE.', 'Pregnancy is not to be considered as an AE; however, is an important medical event that must', 'be monitored as described in Section 7.2.2.2.5.', '7.2.2.1.2', 'Serious Adverse events', 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:', 'Results in death,', 'Is life-threatening,', 'Requires inpatient hospitalization or prolongation of existing hospitalization,', 'Results in persistent or significant disability/incapacity, or', 'Is a congenital anomaly/birth defect.', 'Important medical events that may not result in death, be life-threatening, or require hospitalization', 'may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize', 'the safety of the subject and may require medical or surgical intervention to prevent one of the', 'outcomes listed in this definition. Examples of such events are intensive treatment in an emergency', 'room or at home for allergic bronchospasm, blood dyscrasia, or convulsions that do not result in', 'hospitalization.']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 44 of 88', 'Note:', 'The term \"life-threatening\" refers to an event in which the subject was at risk of death at the time', 'of the event; it does not refer to an event that hypothetically might have caused death if it was more', 'severe.', 'Inpatient hospitalization is considered to have occurred if the subject has had to stay for a night at', 'the hospital. The criterion for prolongation of hospitalization is also defined as an extra night at', 'the hospital. Hospitalization may not constitute sufficient grounds to be considered as an SAE if it', 'is solely for the purpose of a diagnostic tests (even if related to an AE), elective hospitalization for', 'an intervention that was already planned before subject enrollment in the clinical trial, admission', 'to a day-care facility, social admission (e.g., if the subject has no place to sleep), or administrative', 'admission (e.g., for a yearly examination).', '7.2.2.1.3', 'Adverse Events of Special Interest', 'An AESI is a noteworthy event for the particular study drug that can be appropriate to monitor', 'closely. It could be serious or non-serious and AESIs could include events that might be potential', 'precursors or prodromal symptoms for more serious medical conditions in susceptible individuals.', 'CCI', 'For AESIs, the Investigator is required to complete the Adverse Event Form and follow the AESI', 'reporting procedures in Section 7.2.2.2.3 even if the event is considered non-serious according to', 'the usual regulatory criteria. For suspected sensitizations follow challenge and re-challenge patch', 'test procedures in Section 7.2.2.2.4.', '7.2.2.1.4', 'Unexpected adverse drug reaction', 'According to ICH E6, an unexpected adverse drug reaction is defined as an adverse reaction, the', 'nature or severity of which is not consistent with the applicable study drug information (e.g., IB', 'for an unapproved investigational product or the package insert/summary of product characteristics', 'for an approved product).', '7.2.2.1.5', 'Adverse event reporting period', 'The clinical trial period during which AEs must be reported is the period from when the subject', \"signed the ICF to the end of the subject's participation.\"]\n\n###\n\n", "completion": "END"}